ArticleBMC veterinary research2025
A novel linear B-cell epitope on S2 protein of transmissible gastroenteritis virus identified using a monoclonal antibody.
Article in BMC veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundTransmissible gastroenteritis virus (TGEV) is a devastating coronavirus that causes severe gastrointestinal symptoms and high mortality in piglets, resulting in substantial economic losses in the swine industry. The spike (S) protein, particularly its S2 subunit, plays a crucial role in virus-host membrane fusion and exhibits high conservation among TGEV strains. However, B-cell epitopes within the TGEV S2 protein remain largely uncharacterized. This study aimed to express and purify the TGEV S2 protein, generate monoclonal antibodies (mAbs) against it, and identify specific B-cell epitopes.
resultsWe successfully expressed and purified the TGEV S2 protein using a prokaryotic expression system. Immunization of BALB/c mice with the purified S2 protein yielded mAb 12G8, characterized as an IgG2b isotype with a kappa light chain. The mAb 12G8 demonstrated specific reactivity against TGEV strains through multiple immunological assays. Epitope mapping identified 1109QGQALS1114 as the minimal B-cell specific epitope recognized by mAb 12G8, which exhibits high conservation across different TGEV strains. Three-dimensional structural modeling analysis localized this conserved epitope within the heptad repeat 1 domain of TGEV S2 protein.
conclusionsThese findings advance the understanding of TGEV S2 protein antigenicity and provide valuable resources for developing improved diagnostic tools and therapeutic strategies against TGEV infection. The identification of a conserved B-cell epitope within the S2 protein establishes new avenues for targeted vaccine development and may contribute to more effective control measures against TGEV in the swine industry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.